awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CC
Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CC
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.
P2860
Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
17f7ac58aa7fd8105a8bfa526c79c60ee3e9aac5
P2860
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.